Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight-loss drugs Ozempic and ...

Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...

A once-weekly dose of tirzepatide (Mounjaro) can lead to significant, sustained weight loss for up to 3 years in adults with ...

Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the US. Participants experienced an average weight loss of 7.2 kg with the 36 mg ...

Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the ...

Amy Schumer has shared on update on her weight loss journey after speaking out the side effects she experienced using Ozempic ...

The once-daily pill, currently under investigation, is being studied for adults with type 2 diabetes who are not on any ...

Westport makes the world’s entire supply of the anti-wrinkle drug — now it fears production could move to the US ...

Long-term use of tirzepatide shows sustained and significant weight loss in adults with overweight or obesity.

Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...